| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health |
NCT03712280: MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) |
|
|
| Completed | 2a | 50 | US | MNK6106, Study Drug, L-Ornithine Phenylacetate, Rifaximin, Xifaxan | Mallinckrodt | Hepatic Cirrhosis, Hepatic Encephalopathy (HE) | 07/20 | 07/20 | | |
NCT00281502: The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy |
|
|
| Unknown status | 2 | 50 | US | Rifaximin (drug), Xifaxan | Weill Medical College of Cornell University, Bausch Health Americas, Inc. | Hepatic Encephalopathy, Hepatitis C, Liver Cirrhosis | 12/12 | 12/12 | | |
NCT02334163: The Effects of Nitazoxanide in Hepatic Encephalopathy |
|
|
| Unknown status | 2 | 36 | RoW | Nitazoxanide, Oral lactulose, Metronidazole, Rifaximine | Ain Shams University, Al-Azhar University | Hepatic Encephalopathy | 02/15 | 04/15 | | |
NCT03515044: Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE) |
|
|
| Completed | 2 | 71 | US | 40 mg Rifaximin SSD once daily, 40 mg Rifaximin SSD twice daily, 80 mg Rifaximin SSD once daily, 80 mg Rifaximin SSD twice daily, Placebo | Bausch Health Americas, Inc. | Overt Hepatic Encephalopathy | 03/20 | 03/20 | | |
|
NCT01069133: Study of Rifaximin in Minimal Hepatic Encephalopathy |
|
|
| Completed | 1/2 | 20 | US | Rifaximin, xifaxan, rifaximin | Hunter Holmes Mcguire Veteran Affairs Medical Center, Bausch Health Americas, Inc. | Minimal Hepatic Encephalopathy | 05/12 | 12/12 | | |
NCT02931123: A RCT COMPARING LACTULOSE AND RIFAXIMIN ASSOCIATED WITH A VEGETABLE DIET IN THE PREVENTION OF POST-TIPS OVERT HEPATIC ENCEPHALOPATHY |
|
|
| Unknown status | 1/2 | 58 | Europe | lattulose and rifaximine | University of Roma La Sapienza | Cirrhotic Patients Undergoing TIPS Placement | 11/17 | 11/18 | | |
